Lecture

Gastrointestinal cancer in China 2019 meeting Summary

Expand

Received date: 2020-01-14

  Online published: 2020-04-25

Cite this article

LU Sheng, YAN Chao, LI Chen, ZHANG Jun, YAN Min, ZHU Zhenggang . Gastrointestinal cancer in China 2019 meeting Summary[J]. Journal of Surgery Concepts & Practice, 2020 , 25(02) : 178 -180 . DOI: 10.16139/j.1007-9610.2020.02.020

References

[1] Ji J, Liang H, Xue Y, et al. Peri/post-operative chemotherapy of oxaliplatin combined with S-1 (SOX) versus post-operative oxaliplatin with capecitabine (XELOX) in locally advanced gastric cancer: RESOLVE Trial[J]. J Clin Oncol, 2017, 35(15 Suppl):e15519.
[2] Kodera Y, Yoshida K, Kochi M, et al. A randomized phase Ⅲ study comparing S-1 plus docetaxel with S-1 alone as a postoperative adjuvant chemotherapy for curatively resected stageⅢ gastric cancer (JACCRO GC-07 trial)[J]. J Clini Oncol, 2018, 36(15 Suppl):4007.
[3] Terashima M, Yoshida K, Rha SY, et al. International retrospective cohort study of conversion therapy for stage Ⅳ gastric cancer 1 (CONVO-GC-1)[J]. J Clin Oncol, 2018, 36(15 Suppl):4042.
[4] Kang YK, Yook JH, Ryu MH, et al. A randomized phase Ⅲ study of neoadjuvant chemotherapy with docetaxel(D), oxaliplatin(O), and S-1(S) (DOS) followed by surgery and adjuvant S-1 vs. surgery and adjuvant S-1 for resectable advanced gastric cancer(PRODIGY)[J]. J Clin Oncol, 2015, 33(15 Suppl):TPS4136.
[5] 严超, 燕敏, 朱正纲. 胃癌腹膜转移的转化治疗策略:新辅助腹腔内联合全身化疗[J]. 外科理论与实践, 2017, 22(1):28-31.
Outlines

/